Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
about
Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assaysAntitoxin Treatment of Inhalation Anthrax: A Systematic ReviewAerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatmentMucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccineInhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremiaIdentification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression systemEfficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthraxRecombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxComparison of three anthrax toxin neutralization assaysAnthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.Establishing efficacy of human products using animals: the US food and drug administration's "animal rule".Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodiesRecombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthraxA three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaquesPast, imminent and future human medical countermeasures for anthrax.Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple speciesPathology and pathophysiology of inhalational anthrax in a guinea pig model.Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits.Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model.Macaque models of human infectious disease.Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthraxAnthrax lethal toxin and the induction of CD4 T cell immunity.Anthrax vaccines: present status and future prospects.Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule.The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.Murine macrophages kill the vegetative form of Bacillus anthracisNeutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
P2860
Q28383562-0C00D409-2571-44EB-A26B-E7F771A21C8AQ28383765-A4324D22-6410-4E7F-B6E5-DE99CB2B5B64Q28385233-8ECD36BE-D7C6-4558-9780-499F23E8D6C9Q28387065-4099CC27-8776-4423-8ECE-FD87B6D30B8EQ28387410-089D28C3-6AD0-409A-9674-E7B09604D8AFQ28388913-B188A967-0B3B-45C1-A2FF-C5052CD1CE5FQ28389738-23EF9188-54B4-4FB6-9833-E1B826151431Q33258307-9BD86796-725E-474A-BB56-09ACEF8B934AQ33396429-AB05F507-97C2-4193-AA84-C77B5E1A941DQ33550670-FDB924ED-EF00-4EE7-95FD-C8E1069222B8Q33783323-2D9C71F7-B2FC-4639-8FF2-EDC1E8AEFAB6Q34121007-B24529C1-1143-46C8-AEA7-394ED3B952C2Q34121874-6F60D69C-5240-4B20-AE52-735217D723AAQ34303179-738BA745-5CEF-4D84-BDC0-9092ED43799FQ34334451-465049DC-309C-4829-8FD3-8C460079457AQ36378590-BE282B79-7909-41B5-B8F2-78A2521FAC81Q36565152-7DF8EE25-DC38-42FE-BEC2-62929352D3C7Q36746871-F1FD31B0-358E-4ADB-8F75-1F9E113B48E8Q36804713-E1744D0B-B870-4BC3-9E70-8FCCD7999A64Q36901955-71F14649-B2D1-4588-AFBA-AEDF3A2989D0Q36949041-67AF2711-6281-47D8-A547-F13E5D33471EQ37033041-8EA31716-3AA8-40B0-886F-143C8CD436D1Q37103536-4BBD2EF7-CA01-4A13-8399-D7CBAB6BC36CQ37145046-4329764F-61A0-47B2-AA1E-9F7B9AEC869BQ38060730-39B2B971-F303-4DF8-9D12-BD47E01B9802Q38132268-2A368E27-300B-4749-AB59-8B467D7ABE9EQ38993775-1666C66F-A040-4CEB-A1DD-3A41CFB23CE8Q39205816-8C713A84-2850-495C-AC8F-C6CD51C28C94Q39394058-C664A1EA-956D-477E-913E-5714197CE904Q40046283-927A0925-AA0B-4D69-AB88-360D7D022694Q41813154-F966F2FE-B361-4C46-9F52-146167A48BFFQ46936728-9A1D74A0-8495-4862-BE6C-25D5764C7912
P2860
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@ast
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@en
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@nl
type
label
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@ast
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@en
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@nl
prefLabel
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@ast
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@en
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@nl
P2093
P2860
P1476
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
@en
P2093
Andrew J Phipps
Christopher Premanandan
Michael D Lairmore
Roy E Barnewall
P2860
P304
P356
10.1128/MMBR.68.4.617-629.2004
P407
P577
2004-12-01T00:00:00Z